Shares of Teva Pharmaceutical Industries Limited (NYSE: TEVA – Get a rating) have been assigned an average rating of “Hold” by the nine rating agencies that cover the company, market beat reports. Two investment analysts rated the stock with a sell recommendation, two gave the company a hold recommendation and five gave the company a buy recommendation. The 12-month average price target among brokerages that have reported on the stock over the past year is $10.67.
TEVA has been the subject of several analyst reports. StockNews.com began covering shares of Teva Pharmaceutical Industries in a report on Wednesday, October 12. They set a “buy” rating for the company. Bank of America upgraded shares of Teva Pharmaceutical Industries from a “neutral” rating to a “buy” rating and raised its price target for the company from $10.00 to $13.00 in a research note from the Friday August 5th. UBS Group upgraded Teva Pharmaceutical Industries from a “neutral” rating to a “sell” rating in a report released on Friday. Jefferies Financial Group reaffirmed a “buy” rating and set a target price of $10.00 on shares of Teva Pharmaceutical Industries in a Friday, October 21 research note. Finally, Goldman Sachs Group raised its price target on Teva Pharmaceutical Industries from $9.00 to $10.00 and gave the company a “neutral” rating in a Tuesday, August 2 report.
Insider buying and selling
In other news, CFO Eliyahu Sharon Kalif sold 55,500 shares of the company in a transaction dated Monday, August 22. The shares were sold at an average price of $10.07, for a total transaction of $558,885.00. Following the completion of the transaction, the CFO now owns 9,376 shares of the company, valued at approximately $94,416.32. The transaction was disclosed in a legal filing with the SEC, accessible via the SEC website. 0.82% of the shares are held by insiders.
Institutional investors weigh in on Teva Pharmaceutical Industries
Institutional investors and hedge funds have recently changed their stock holdings. Private Trust Co. NA acquired a new stake in shares of Teva Pharmaceutical Industries during the second quarter at a value of $32,000. Crédit Agricole SA bought a new stake in Teva Pharmaceutical Industries during the second quarter, valued at around $34,000. Aaron Wealth Advisors LLC acquired a new stake in Teva Pharmaceutical Industries during the first quarter worth approximately $603,000. Newbridge Financial Services Group Inc. increased its holdings of Teva Pharmaceutical Industries shares by 555.6% in the third quarter. Newbridge Financial Services Group Inc. now owns 5,900 shares of the company worth $48,000 after purchasing an additional 5,000 shares during the period. Finally, Evolution Wealth Advisors LLC bought a new position in Teva Pharmaceutical Industries stock in the first quarter worth about $94,000. Institutional investors and hedge funds hold 46.22% of the company’s shares.
Teva Pharmaceutical Industries is trading down 1.6%
NYSE: TEVA opened at $8.47 on Friday. The company has a market capitalization of $9.41 billion, a P/E ratio of -8.92, a P/E/G ratio of 3.56 and a beta of 1.27. The company has a 50-day simple moving average of $8.54 and a 200-day simple moving average of $8.61. The company has a debt ratio of 2.07, a current ratio of 1.11 and a quick ratio of 0.74. Teva Pharmaceutical Industries has a 12-month low of $6.78 and a 12-month high of $11.34.
About Teva Pharmaceutical Industries
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets and distributes generic drugs, specialty drugs and biopharmaceuticals in North America, Europe and internationally. The company offers sterile products, hormones, high potency drugs and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments and creams.
Further reading
This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to contact@marketbeat.com.
Before you consider Teva Pharmaceutical Industries, you’ll want to hear this.
MarketBeat tracks daily the highest rated and most successful research analysts on Wall Street and the stocks they recommend to their clients. MarketBeat has identified the five actions that top analysts are quietly whispering to their clients to buy now before the market spreads…and Teva Pharmaceutical Industries was not on the list.
While Teva Pharmaceutical Industries currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.
